The value of tumor markers in men with metastatic prostate cancer undergoing [ 177 Lu]Lu‐PSMA therapy-Reference-Cited by-同舟云学术

The value of tumor markers in men with metastatic prostate cancer undergoing [ 177 Lu]Lu‐PSMA therapy

Published:2019-10-03 Issue:1 Volume:80 Page:17-27
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Yordanova Anna¹^ORCID,Linden Paula¹,Hauser Stefan²,Feldmann Georg³,Brossart Peter³,Fimmers Rolf⁴,Essler Markus¹,Holdenrieder Stefan⁵,Ahmadzadehfar Hojjat¹

Affiliation:

1. Department of Nuclear MedicineUniversity Hospital BonnBonn Germany

2. Department of UrologyUniversity Hospital BonnBonn Germany

3. Department of Internal Medicine 3University Hospital BonnBonn Germany

4. Institute for Medical Biometry, Informatics and EpidemiologyUniversity of BonnBonn Germany

5. Institute for Laboratory Medicine, German Heart CentreTechnical University of MunichMunich Germany

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23912

Reference69 articles.

1. Targeting prostate‐specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises;Santoni M;J Biol Regul Homeost Agents,2014

2. Prostate‐specific membrane antigen expression in normal and malignant human tissues;Silver DA;Clin Cancer Res,1997

3. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique

4. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

5. Targeted treatment of prostate cancer

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

3. Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with ‘PSA Pseudoregression’ Response Pattern;Nuklearmedizin - NuclearMedicine;2024-05-17

4. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?;Translational Cancer Research;2023-10

5. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study;European Urology Oncology;2023-08